Evidence map›Paper›PMID 38807304›Full record

ArticleMolecular oncology2024

Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density.

Jonas Wohlfarth, Corinna Kosnopfel, Dominic Faber, Marion Berthold, Claudia Siedel, Melissa Bernhardt, Andreas Schlosser, Tyler Aprati, David Liu, David Schrama and 5 more

Abstract read
In one paragraph

Article in Molecular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jonas WohlfarthDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany.ORCID 0009-0002-4536-3625
Corinna KosnopfelDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany.ORCID 0000-0002-0910-838X
Dominic FaberDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany.
Marion BertholdDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany.
Claudia SiedelDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany.
Melissa BernhardtRudolf-Virchow-Centre for Integrative and Translational Bioimaging, University of Würzburg, Germany.
Andreas SchlosserRudolf-Virchow-Centre for Integrative and Translational Bioimaging, University of Würzburg, Germany.
Tyler ApratiDana-Farber Cancer Institute, Boston, MA, USA.
David LiuDana-Farber Cancer Institute, Boston, MA, USA.
David SchramaDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany.
Roland HoubenDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany.ORCID 0000-0003-4538-2324
Dirk SchadendorfDepartment of Dermatology, Comprehensive Cancer Center (Westdeutsches Tumorzentrum), German Cancer Consortium (DKTK, partner site Essen) and University Hospital Essen, Germany.
Matthias GoebelerDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany.
Svenja MeierjohannInstitute of Pathology, University of Würzburg, Germany.
Bastian SchillingDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany.ORCID 0000-0001-8859-4103

Funding

Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational OncologyK08CA234458 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LIU, DAVID · 2018 to 2022
$1.2M
NCI NIH HHS K08 CA234458
6 · The paper itself

Abstract

Immunotherapy has achieved tremendous success in melanoma. However, only around 50% of advanced melanoma patients benefit from immunotherapy. Cyclin-dependent kinase inhibitor 2A (CDKN2A), encoding the two tumor-suppressor proteins p14

Indexed as

MelanomaTumor Suppressor Protein p14ARFWnt Signaling PathwayAntigen PresentationAntigens, NeoplasmCell Line, TumorHistocompatibility Antigens Class IHumansPeptidesT-LymphocytesWnt-5a ProteinAntigens, NeoplasmHistocompatibility Antigens Class IPeptidesTumor Suppressor Protein p14ARFWnt-5a ProteinWNT5A protein, humanCDKN2Aimmunogenicityimmunotherapymelanomapeptide surface densityWnt signaling

Identifiers

PMID38807304
PMCPMC11459041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.